Patient Education Driving BTK Inhibitor Treatment Adherence

EP: 1.Clinical Characteristics Distinguishing CLL and SLL

EP: 2.Quality of Life Impacted By CLL and SLL Diagnosis and Management

EP: 3.Evaluating Current Treatment Landscape of CLL and SLL

EP: 4.Unmet Needs In CLL and SLL Treatment Management

EP: 5.Indications and Considerations For BTK Inhibitor Use In CLL and SLL Management

EP: 6.Examining Safety and Efficacy of BTK Inhibitors In CLL and SLL Treatment

EP: 7.Determining Optimal CLL / SLL Therapy: Ibrutinib, Acalabrutinib and Zanubrutinib

EP: 8.Key Highlights From ASH 2023

EP: 9.Economic Burden Associated With BTK Inhibitor Use

Now Viewing

EP: 10.Patient Education Driving BTK Inhibitor Treatment Adherence

EP: 11.Optimizing BTKi Treatment Strategies

EP: 12.Key Considerations for Treating Patients Diagnosed With CLL and SLL

This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA, CPEL; Tara Graff, DO, MS; Ryan Jacobs, MD; Deborah Stephens, DO; Jennifer Woyach, MD.

The group discusses considerations for educating and empowering patients receiving Bruton tyrosine kinase inhibitor (BTKi) therapy. As BTKis are given continuously long term, Dr Jacobs conceptualizes treatment as a marathon for patients. He emphasizes being upfront about common adverse effects and setting the expectation that doses can be reduced to mitigate toxicities without losing efficacy. This encourages patients to promptly communicate issues rather than try to push through them.

The experts recommend a patient-centered, shared decision-making approach involving the full care team, including pharmacy and nursing, to provide context and resources to help patients work through any adverse effects. Monitoring abandonment rates is also important to ensure patients from all backgrounds can remain on these long-term therapies. Effective patient education and support systems are crucial to facilitate optimal adherence throughout BTKi treatment.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.